USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/18193
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGavriliuc, Olga
dc.contributor.authorAndrușca, Alexandru
dc.contributor.authorPopil, Lilian
dc.contributor.authorGavriliuc, Mihail
dc.date.accessioned2021-10-16T18:35:07Z
dc.date.available2021-10-16T18:35:07Z
dc.date.issued2021
dc.identifier.citationGAVRILIUC, Olga, ANDRUSCA, Alexandru, POPIL, Lilian, GAVRILIUC, Mihail. Low-dose anticholinergic therapy causes cognitive impairment in Parkinson’s disease patients. In: The Moldovan Medical Journal. 2021, vol. 64, no 4, pp. 66-68. ISSN 2537-6381. https://doi.org/10.52418/moldovan-med-j.64-4.21.12
dc.identifier.issn2537-6381
dc.identifier.issn2537-6373
dc.identifier.urihttp://moldmedjournal.md/wp-content/uploads/2021/10/Moldovan-Med-J-Vol-64-No-4-vers-5.pdf
dc.identifier.urihttps://doi.org/10.52418/moldovan-med-j.64-4.21.12
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/18193
dc.description.abstractBackground: Before L-Dopa’s discovery, anticholinergic drugs were among the first treatments for Parkinson’s disease. Only now trihexyphenidyl (THP) is approved to treat unresponsive L-dopa tremors in young, cognitively unaffected Parkinson’s disease patients. However, there are no specific recommendations for disease duration, medication dose, or cognitive status. In low-income countries, THP is still frequently used in Parkinson’s disease patients with tremor. The objective of the current study was to evaluate cognitive performance in Parkinson’s disease patients receiving a low dose of THP. Material and methods: The study was performed on nineteen PD patients, nine of whom were on THP. All patients completed MoCA cognitive assessment. The patients were matched depending on their age, disease severity based on UPDRS III and duration of the disease. Results: The THP patients were taking an average dose of 3.3 mg of THP daily for an average of 1.8 years. There were no statistical differences between THP patients and non-THP patients in age (64.8± 4.8 vs 67.2±6.9, p=0.4), UPDRS III (32.1±8.9 vs 41.5±20.6, p=0.2) and disease duration (6.2±4.9 vs 7.0 ± 4.0, p=0.7). The THP patients had lower cognitive performance, with a total MoCA of 19.22 ± 3.3 vs. non-THP patients 24.2±3.0, p=0.003. Conclusions: In Parkinson’s disease patients, even a low dose of THP causes significant cognitive loss.en_US
dc.language.isoenen_US
dc.publisherThe Scientific Medical Association of the Republic of Moldovaen_US
dc.relation.ispartofThe Moldovan Medical Journalen_US
dc.subjectParkinson’s diseaseen_US
dc.subjectcognitionen_US
dc.subjectdementiaen_US
dc.subjectanticholinergicen_US
dc.subject.ddcUDC: 616.858-085.214en_US
dc.titleLow-dose anticholinergic therapy causes cognitive impairment in Parkinson’s disease patientsen_US
dc.typeArticleen_US
Appears in Collections:The Moldovan Medical Journal. Vol. 64, No 4, October 2021

Files in This Item:
File Description SizeFormat 
Low_dose_anticholinergic_therapy_causes.pdf143.17 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback